enGenes to showcase latest iCAP continuous pDNA production technology at BioProcess Summit Europe 2026

Vienna, Austria – enGenes Biotech will showcase its industry-leading automated and continuous plasmid DNA (pDNA) production capabilities at the annual BioProcess Summit Europe 2026 in Barcelona.

The enGenes team, led by CEO Dr. Juergen Mairhofer, will contribute to the Summit’s Intensified and Continuous Processing stream with a presentation demonstrating the impact of its iCAP platform on next-generation plasmid DNA manufacturing.

iCAP: Unlocking continuous bioprocessing

On the morning of day 3 (Thursday, March 12 at 11:40), Dr. Mairhofer will present in the session Unlocking Sustainable Bioprocessing on the topic: “Integrated Continuous and Automated Platform for Plasmid Production.”

His presentation will address how conventional batch production – often costly and yield-limited – constrains plasmid DNA’s growing role in enabling viral vectors, mRNA vaccines, and DNA therapeutics.

The proprietary iCAP platform developed by enGenes replaces traditional batch approaches with a fully integrated continuous and automated microbial process, combining bioprocess intensification with advanced digital intelligence. To read more follow: https://www.pharmaceutical-networking.com/engenes-to-showcase-latest-icap-continuous-pdna-production-technology-at-bioprocess-summit-europe-2026/